K. S. Ataman

K. S. Ataman

Auto-generated profile, based on publicly available information

K. S. Ataman

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
KAK. S. Ataman
K. S. Ataman
НТНаталья Трушенко
Наталья Трушенко
SASergey Avdeev
Sergey Avdeev
Physical intolerance is an important sign of many chronic respiratory diseases. The most useful tool for clinical evaluation of physical status is six-minute walking test (6-MWT), but sometimes its technical requirements are not feasible. By this reason, a search for alternative field tests have being going on in the last years, but the diagnostic yield of the new exercise tests for most chronic bronchopulmonary diseases is not clear.The aim of this study was to compare results of 6-MWT and 30-seconds sit-to-stand (30-s-STS) test in patients with fibrosing interstitial lung diseases (ILDs) and restrictive abnormalities of lung function.Methods. This was a cross-sectional non-randomized open comparative study. Patients with ILDs were asked to perform 6-MWT and 30-s-STS test with 30 min interval. We also analyzed medical history, lung function, and dyspnea assessed with Medical Research Council (MRC).Results. The study included 25 ILD patients (11 males; 14 women); 75% of patients had restrictive lung function disorders. The mean distance walked in 6-MWT (6MD) was 380.4 ± 111.9 m (M ± SD), 14 (56%) patients desaturated during the test. The mean number of repetitions in 30-s-STS test was 12 (10 – 13) during 30 s; 5 (20%) patients desaturated during the test. 6MD showed moderate correlation with the number of repetitions in 30-s-STS test and to dyspnea on exertion. The number of repetitions in the 30-s-STS test was not associated with any clinical or functional parameters. To the end of exercise, the number of patients who desaturated increased, the desaturation was greater, and post-exercise SpO2 was lower in 6-MWT compared to 30-s-STS test.Conclusion. 30-s-STS test was less informative in terms of reduced physical tolerance and desaturation on exertion compared to 6-MWT in patients with fibrosing ILDs and restrictive abnormalities of lung function.

27 May 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
NTN. A. Tsareva
N. A. Tsareva
GNGalina Nekludova
Galina Nekludova
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
GNG. S. Nuralieva
G. S. Nuralieva
FKF. T. Kurkieva
F. T. Kurkieva
SASergey Avdeev
Sergey Avdeev
For the first time, the effectiveness and safety of high doses of inhaled nitric oxide (iNO) in patients with community-acquired pneumonia (CAP) has been demonstrated.The aim of the study was to examine the effectiveness and safety of adding iNO to standard treatment for patients with CAP.Methods. A pilot, single-center, prospective, randomized, open-label clinical trial was conducted, which included patients (n = 120) hospitalized with CAP. Randomization was carried out using the blind envelope method. Patients in the main group (n = 60) received iNO through nasal cannulas using the Tianox iNO therapy device (AIT-NO-Ol according to TU 32.50. 21-001-07623615-2017) in addition to the therapy according to the standard of care at the study center. Inhalations were carried out with high doses of NO, namely 200 ppm for 15 minutes 3 times a day, regardless of food intake. Patients in the control group (n = 60) received only the therapy recommended by the standard of care at the study center. Clinical and laboratory parameters were assessed and safety of the therapy was monitored during the study.Results. No significant differences were identified between the main group and the control group in demographic, clinical, laboratory and instrumental data at baseline. Patients receiving iNO as an adjunct to standard therapy had a more significant improvement in clinical symptoms starting from the 3rd day and better oxygenation parameters on the 7th day of therapy. There was a more significant decrease in the level of C-reactive protein on the 5th and 7th days of therapy and a more significant decrease in the level of leukocytes on the 5th day in the main group. The duration of hospitalization in the main group was significantly shorter than that in the control group. NO inhalation was not associated with any side effects and was well tolerated.Conclusion. The use of high doses of NO has a positive effect on the clinical status, markers of inflammation, reduces the length of hospitalization, and demonstrates good tolerability and safety in patients with CAP.

17 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SASergey Avdeev
Sergey Avdeev
NTN. A. Tsareva
N. A. Tsareva
GNGalina Nekludova
Galina Nekludova
GNG. S. Nuralieva
G. S. Nuralieva
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
The use of nitric oxide is widespread in medical practice. Inhaled form of NO in patients with respiratory disease is especially interesting. As an inhalation therapy, nitric oxide reaches well-ventilated areas of the lungs, having a negligible systemic effect due to its rapid inactivation in the bloodstream. It has long been known that inhaled NO improves oxygenation in various pathological conditions. Low doses of inhaled nitric oxide are known as a vasodilator in patients with pulmonary hypertension, its use is possible even in newborns with hypoxemic respiratory failure and persistent pulmonary hypertension. In turn, high doses are used in the treatment of infectious lung diseases, besides, another surge of scientific interest in nitric oxide arose during the coronavirus pandemic. Although the antimicrobial potential of nitric oxide is widely known, it is little used in clinical practice. Endogenous antimicrobial activity is largely mediated by high local concentrations of NO. Numerous preclinical studies have demonstrated that NO has general static and bactericidal activity against viruses, bacteria, protozoa and fungi/yeast in vitro. Due to the dose-dependent positive and negative effects of NO, safety and efficacy tests of NO and its donors are needed to assess their role in the prevention and treatment of infections. This review provides information on the chemical structure, features of metabolism and delivery of inhaled NO, and also pays special attention to the antimicrobial effect in various diseases of the pulmonological profile.

14 July 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
APA. A. Proshkina
A. A. Proshkina
NTN. A. Tsareva
N. A. Tsareva
GNGalina Nekludova
Galina Nekludova
KAK. S. Ataman
K. S. Ataman
DZDaria Zhukova
Daria Zhukova
SASergey Avdeev
Sergey Avdeev
Introduction . Pulmonary hypertension (PH) frequently complicates the course of idiopathic pulmonary fibrosis (IPF) and worsens its prognosis; however, echocardiographic signs of right heart chamber remodeling and clinical and functional factors associated with systolic pulmonary artery pressure (PASP) level in IPF remain insufficiently studied. Aim . To characterize echocardiographic changes in the right heart chambers in patients with idiopathic pulmonary fibrosis depending on the presence of pulmonary hypertension and to identify clinical and functional factors associated with the value of systolic pulmonary artery pressure. Materials and methods. The study included 121 patients with IPF. Based on echocardiography, patients were divided into groups without PH (PASP < 35 mmHg, n = 35) and with PH (PASP ≥ 35 mmHg, n = 86). Right atrial area (RA area), mean right ventricular diameter (RV diameter), TAPSE, TAPSE/PASP ratio, and left ventricular ejection fraction (LVEF) were assessed. Spearman correlation analysis, univariate and multivariate linear regression analysis with PASP as a continuous variable were performed. Results. The PH group showed larger RA area (17.0 vs 13.5 cm², p < 0.001), larger RV diameter (4.00 vs 3.75 cm, p < 0.001), and a lower TAPSE/PASP ratio (0.438 vs 0.697, p < 0.001) with no difference in absolute TAPSE (p = 0.941). LVEF was slightly lower in the PH group (61% vs 62%, p = 0.016) but remained within normal limits. PASP correlated positively with RA area (r = 0.491, p = 0.019) and desaturation level during 6MWT (r = 0.355, p < 0.001), and negatively with post-exercise SpO₂ (r = -0.336, p = 0.001). DLCO correlated positively with post-exercise SpO₂ (r = 0.347, p = 0.001) and negatively with mMRC (r = -0.338, p = 0.001) and desaturation (r = -0.270, p = 0.014). Univariate linear regression showed associations of PASP with cardiovascular events (β = 10.8), CHF (β = 10.9), desaturation (β = 1.02 per 1%), post-exercise SpO₂ (β = -0.603), mMRC (β = 4.52), LTOT duration (β = 3.74 per year), and LVEF (β = -0.562). In multivariate linear regression, independent determinants of PASP were the Charlson comorbidity index (β = 2.205 per 1 point; p = 0.006), desaturation level (β = 1.153 per 1%; p < 0.001), and LTOT duration (β = 4.281 per year; p = 0.020). Conclusion . In patients with IPF, pulmonary hypertension is associated with right heart remodeling (enlarged RA area, RV diameter) and reduced right ventricular-pulmonary arterial coupling (decreased TAPSE/PASP ratio) despite preserved TAPSE. Independent determinants of PASP value are comorbidity burden (Charlson index), desaturation during exercise, and long-term oxygen therapy duration.

9 October 2025 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
KAK. S. Ataman
K. S. Ataman
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
GNGalina Nekludova
Galina Nekludova
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
SASergey Avdeev
Sergey Avdeev
Interstitial lung disease (ILD) is a diverse and heterogenous group of chronic lung diseases affecting lung parenchyma and characterized by inflammation followed by pulmonary fibrosis that can progress and lead to hospitalization. The impact of hospitalizations on the clinical course of ILD is not fully understood. The aim was to analyze the causes of hospitalization related to the underlying disease and their relationship with the clinical and functional features of the disease course in patients with fibrosing ILD (f-ILD). Methods. This study was an open comparative non interventional study. We analyzed findings from two groups of patients with f-ILD, who had or did not have hospitalizations due to respiratory reasons during the previous 12 months. Additionally, we analyzed demographic and clinical data, severity of ILD according to Gender, Age, Physiology (GAP) scale, lung function and echocardiographic parameters, physical tolerance in 6-minute walk test (6MWT), and pharmacological therapy. Results. Ninety-five patients with f-ILD were involved in the study. Of them, 37 patients had one to four previous hospitalizations due to respiratory reasons during the previous 12 months, and 58 patients did not have any hospitalizations during this period. Most frequent reasons for hospitalization were progressing or exacerbation of f-ILD, less frequent reasons were community-acquired pneumonia and other respiratory infections, and pulmonary embolism. One third of the patients (n = 29) were hospitalized for elective procedures to verify the diagnosis. Patients with previous hospitalizations had more severe course of f-ILD according to GAP scale, lower parameters of lung function, oxygenation, and physical tolerance and more often were treated with pharmacological agents and supplemental oxygen. Conclusion. Most common reasons for hospitalization of f-ILD patients were progressing or exacerbation of f-ILD and the need in elective procedures to verify the diagnosis. Patients hospitalized for respiratory reasons during the previous 12 months had more severe clinical course of the disease with lower lung function and physical tolerance and more often required pharmacological therapy and supplemental oxygen as compared to the patients who had no hospitalizations in this time interval. Further studies are needed to investigate the prognostic value of hospitalizations in f-ILD.

2 July 2026 in Journal of Respiratory Medicine
Verified
Journal Article
Closed access
LNL.YU. Nikitina
L.YU. Nikitina
MGM.G. Gumenyuk
M.G. Gumenyuk
VKV.V. Kuzovatova
V.V. Kuzovatova
EFE.N. Fartushny
E.N. Fartushny
RAR.M. Aynetdinov
R.M. Aynetdinov
SASergey Avdeev
Sergey Avdeev
Lung auscultation remains a fundamental method for the clinical diagnosis of respiratory diseases; however, its effectiveness is limited by subjective interpretation and interobserver variability (kappa coefficient (Κ) 0.4—0.6). Advances in digital technologies have led to the emergence of electronic auscultation as a tool for the objectification and standardization of auscultatory data. Objective. To systematize data on modern electronic stethoscopes, open-access respiratory sound databases, artificial intelligence (AI) algorithms, and telemedicine capabilities, with an assessment of their clinical applicability. Material and methods. A literature review was conducted using publications retrieved from PubMed/MEDLINE, Embase, IEEE Xplore (Institute of Electrical and Electronics Engineers), and eLIBRARY.RU databases for the period 2000—2025. Results. Modern devices perceive an extended frequency range (up to 2000 Hz), provide recording, visualization, and transmission of data to medical information systems. Deep learning algorithms — convolutional neural networks, long short-term memory networks, and vision transformers — demonstrate classification accuracy of respiratory sounds ranging from 79% to 99% on public datasets. Key limitations identified include the lack of unified data storage standards, inter-device variability in amplitude—frequency characteristics, insufficient clinical validation, and limited integration with international standards for medical data exchange and the Unified State Health Information System. Conclusion. Electronic auscultation is a key component in transition to digital respiratory medicine. Its full-scale implementation requires the development of regulatory standards, creation of multicenter national respiratory sound databases, and clinical validation of AI algorithms.